MONTREAL, QUEBEC--(Marketwire - May 15, 2008) - Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced that the National Association of Pharmacy Regulatory Authorities (NAPRA) has granted Plan B® full Over-the-Counter status (OTC) (schedule III). Previously, Plan B® had behind the counter status (schedule II).
